Report Overview

Indian NSCLC market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Non-small cell lung cancer (NSCLC) is one of the types of Lung Cancer. About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.In India, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer related deaths in both sexes. The detection of cancer cases has enhanced, which has made the delivery of lung cancer treatments such as chemotherapy and surgery easier than before, thus boosting the NSCLC treatment market share's progress in the forecast period.



Market Drivers

An increasing number of diagnoses of non-small cell lung cancer and the increasing awareness in the countries of the developed and developing markets are also contributing towards the non-small cell lung cancer therapeutics market growth. This, coupled with increasing investments by major players in research and development activities, and the inclusion of non-small cell cancer therapeutics in pipelines of major market players are also boosting the market growth. Some of the other factors which are also contributing to the non-small cell lung cancer therapeutics market growth are the increase in the proportion of the smoking population and exposure to toxins such as asbestos. Greater adoption and increasing demand for targeted therapies, which is considered to be the foundation of precision medicine due to the increasing R&D initiatives and also due to its sophistication in targeting cancerous cells, is one of the most prominent leading factors that are responsible for the growth.